Type II Diabetes Mellitus - An Unmet Medical Need: Emerging Targets & Therapies

Aims & scope

Diabetes mellitus (DM) especially type II DM became epidemic in spite of regional disparities. More than 382 million people are suffering from DM and majority. Type II DM (non insulin dependent DM) are poses a serious challenge as more than 90% of diabetic people are suffering from this. Burden of DM increases along with unhealthy lifestyle, obesity, and is responsible for several complications. Type 2 DM becomes increasingly prevalent with advancing age especially after 35 years of age. Risk of cardiovascular diseases, neurodegenerative diseases, gastrointestinal problem, eye problem, skin problem, macro and micro vascular diseases are also compounding as DM progresses. Current therapeutic strategies failed to avert this condition and indicating towards the need of new strategies. Gene therapy, stem cell therapy, cell replacement therapy, and research on DPP-IV inhibitors, PARP inhibitors, GLP-1 inhibitors are increasing continuously with the hope to cure DM. Several biomarkers like adipokines, GAD65, 2-aminoadipic acid etc emerged as potential therapeutic target or approach to treat type II DM.

In this thematic issue, emerging target and therapies of DM will be discusses from a variety of angles, which may present a more inclusive picture regarding the potentialities, hurdles and drawback new therapeutic approaches that can cure type II DM and reduce the risk of diabetic complications. A comprehensive discussion, quality conceptual frameworks, sharing research finding through the contribution of review and research article will enrich the scientific community and also provoke thinking and the development of new ideas or theories.
Subtopics

[Only review articles related to following topics will be preferred]:

- Emerging approaches, drugs and possible targets in management of type II DM
- Gene therapy to cure type II DM
- Stem cell research and its importance in relation with type II DM
- Current investigation on DPP-IV inhibitors, PARP inhibitors, GLP-1 inhibitors
- Role of adipokines, GAD65, 2-aminoacidic acid etc to cure type II DM
- Biomarker of diabetes mellitus
- Hormone replacement therapy and type II DM
- Alternative medicine, traditional medicine in diabetes

Schedule:

Manuscript Submission Deadline: **September 2015**
Peer Review Due: **October 2015**
Revision Due: **15th November 2015**
Publication: Notification of Acceptance: **30th November 2015**